Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer treatment, has announced it will provide a corporate update for Q2 2024 on Tuesday, August 13, 2024. The update will cover the three months ended June 30, 2024. Management will host a conference call and webcast at 8:30 am Eastern Time to discuss financial results and provide an overview. Investors can join the call toll-free at 1-800-717-1738. A replay of the call will be available on the company's investor relations website.
Cellectar Biosciences (NASDAQ: CLRB), un'azienda biopharmaceutica clinica in fase avanzata focalizzata sulla terapia per il cancro, ha annunciato che fornirà un aggiornamento aziendale per il secondo trimestre del 2024 il martedì 13 agosto 2024. L'aggiornamento riguarderà i tre mesi terminati il 30 giugno 2024. Il management ospiterà una chiamata in conferenza e un webcast alle 8:30 ora orientale per discutere i risultati finanziari e fornire una panoramica. Gli investitori possono partecipare alla chiamata gratuitamente al numero 1-800-717-1738. Una registrazione della chiamata sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda.
Cellectar Biosciences (NASDAQ: CLRB), una empresa biofarma clínica en etapa avanzada centrada en el tratamiento del cáncer, ha anunciado que proporcionará una actualización corporativa para el segundo trimestre de 2024 el martes 13 de agosto de 2024. La actualización abordará los tres meses finalizados el 30 de junio de 2024. La dirección llevará a cabo una llamada de conferencia y webcast a las 8:30 a.m. hora del Este para discutir los resultados financieros y ofrecer una visión general. Los inversores pueden unirse a la llamada sin costo al 1-800-717-1738. Una repetición de la llamada estará disponible en el sitio web de relaciones con los inversores de la empresa.
Cellectar Biosciences (NASDAQ: CLRB)는 암 치료에 주력하는 후기 단계 임상 생명공학 회사로, 2024년 2분기 기업 업데이트를 2024년 8월 13일 화요일에 제공할 것이라고 발표했습니다. 이번 업데이트는 2024년 6월 30일 종료된 3개월을 다룰 것입니다. 경영진은 컨퍼런스 콜 및 웹캐스트를 동부 표준시 기준으로 오전 8시 30분에 개최하여 재무 결과를 논의하고 개요를 제공할 예정입니다. 투자자들은 1-800-717-1738로 무료로 통화에 참여할 수 있습니다. 통화의 재생은 회사의 투자자 관계 웹사이트에서 이용할 수 있습니다.
Cellectar Biosciences (NASDAQ: CLRB), une entreprise biopharmaceutique clinique en phase avancée axée sur le traitement du cancer, a annoncé qu'elle fournira une mise à jour corporate pour le deuxième trimestre 2024 le mardi 13 août 2024. La mise à jour couvrira les trois mois se terminant le 30 juin 2024. La direction animera une conférence téléphonique et un webcast à 8h30, heure de l'Est, pour discuter des résultats financiers et donner un aperçu. Les investisseurs peuvent participer à l'appel sans frais au 1-800-717-1738. Un enregistrement de l'appel sera disponible sur le site Web des relations avec les investisseurs de l'entreprise.
Cellectar Biosciences (NASDAQ: CLRB), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Krebsbehandlung konzentriert, hat angekündigt, dass es ein Unternehmensupdate für das zweite Quartal 2024 am Dienstag, den 13. August 2024 bereitstellen wird. Das Update wird sich auf die drei Monate bis zum 30. Juni 2024 beziehen. Das Management wird um 8:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen Ergebnisse zu erörtern und einen Überblick zu geben. Investoren können kostenlos unter der Nummer 1-800-717-1738 an dem Call teilnehmen. Eine Wiederholung des Calls wird auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern Time. Details for the call are as follows:
| Conference Call & Webcast Details: | |
| Date: | Tuesday, August 13, 2024 |
| Time: | 8:30 am Eastern Time |
| Toll Free: | 1-800-717-1738 |
| Webcast: | Click HERE |
A replay of the call will be available on Events section of the company’s investor relations website.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop the next-generation of cancer cell-targeting treatments, delivering improved efficacy and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead asset iopofosine I 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:
Claire LaCagnina
Bliss Bio Health
315-765-1462
clacagnina@blissbiohealth.com
INVESTORS:
Chad Kolean
Chief Financial Officer
investors@cellectar.com
FAQ
When will Cellectar Biosciences (CLRB) announce its Q2 2024 financial results?
What time is Cellectar Biosciences' (CLRB) Q2 2024 earnings call scheduled for?
How can investors access Cellectar Biosciences' (CLRB) Q2 2024 earnings call?
What period will Cellectar Biosciences' (CLRB) Q2 2024 financial results cover?
